Evidence map›Paper›PMID 28756377›Full record

ArticleBMJ case reports2017

Thrombolytic therapy for the treatment of acute ischaemic stroke in adults with homozygous sickle cell disease.

Loubna Majhadi, David Calvet, Charlotte Rosso, Pablo Bartolucci

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Loubna MajhadiAPHP (Assistance publique - Hopitaux de Paris), Servicede Neurologie, Groupe hospitalier Henri-Mondor Albert Chenevier, Créteil, France, Creteil, France.
David CalvetDepartment of Neurology, Univ Paris 05, Paris, France.
Charlotte RossoAssistance Publique - Hopitaux de Paris, Paris, ÃŽle-de-France, France.
Pablo BartolucciAssistance Publique - Hopitaux de Paris, Creteil, ÃŽle-de-France, France.
Assistance Publique – Hôpitaux de Paris · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke is a significant cause of morbidity and mortality in patients with homozygous sickle cell disease (SCD). A specific large-vessel vasculopathy is often responsible for both haemorrhagic and ischaemic strokes in patients with SCD. Although intravenous thrombolysis has been considered as a therapeutic option for acute ischaemic strokes in SCD, its use remains debated because of an increased risk of spontaneous intracranial haemorrhage reported in this disease. This risk of haemorrhage is mainly supported by the presence of a Moyamoya syndrome often associated with the specific vasculopathy in patients with homozygous SCD. We report two cases of patients with homozygous SCD treated with intravenous thrombolysis for an acute ischaemic stroke without haemorrhagic transformation. Our cases suggest that reperfusion strategy in acute ischaemic stroke in patients with homozygous SCD can be considered once associated Moyamoya syndrome has been ruled out. An international registry would be of interest as these situations are rare.

Indexed as

Thrombolytic TherapyAnemia, Sickle CellBrain IschemiaFemaleFibrinolytic AgentsHumansIntracranial HemorrhagesMaleMiddle AgedStrokeTreatment OutcomeYoung AdultFibrinolytic Agentsmoyamoyastroke

Identifiers

PMID28756377
PMCPMC5747609
OpenAlexW2739982626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.